Interpretation of the latest medical insurance policy for Serputinib/Serpatinib

Selpercatinib is a targeted therapy specifically targeting tumors with RET gene abnormalities. Its main indications include locally advanced or metastatic ET fusion-positive non-small cell lung cancer (NSCLC),RET-mutated medullary thyroid carcinoma (MTC), and RET fusion-positive thyroid cancer (TC). This drug interferes with the growth and reproduction of tumor cells by inhibiting the activity of RET kinase, and therefore shows good efficacy in patients with these specific gene mutations. Studies have shown that seputinib has a significant effect in improving patients' progression-free survival and overall survival.

Although the original drug Seputinib has been marketed in China, it has not yet been included in the medical insurance catalog, which makes patients face certain challenges in terms of affordability. According to market information, the price per box of 80mg*56 capsules is expected to exceed RMB 10,000. This price represents a relatively high financial burden for many patients, especially in the context of long-term treatment. Therefore, when choosing a treatment plan, patients need to fully consider their own financial situation and the necessity of treatment.

Regarding the latest medical insurance policy, the medical insurance coverage of seprotinib is currently unclear. Generally speaking, the inclusion of drugs in the medical insurance catalog needs to go through a strict evaluation process, including efficacy, safety and economic evaluation. As the country pays more attention to and invests in cancer treatment drugs, more targeted drugs may gradually enter the medical insurance system in the future, thereby reducing the burden on patients. However, due to the high price of drugs and R&D costs, the inclusion of drugs still requires time and policy support.

Before using seputinib, patients are advised to actively communicate with their doctors to understand the specific conditions of their condition and discuss appropriate treatment options. At the same time, patients can also pay attention to relevant clinical trial information and may have the opportunity to obtain the use of new drugs in the trial.

Reference:https://en.wikipedia.org/wiki/Selpercatinib